MX2020002036A - Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. - Google Patents

Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.

Info

Publication number
MX2020002036A
MX2020002036A MX2020002036A MX2020002036A MX2020002036A MX 2020002036 A MX2020002036 A MX 2020002036A MX 2020002036 A MX2020002036 A MX 2020002036A MX 2020002036 A MX2020002036 A MX 2020002036A MX 2020002036 A MX2020002036 A MX 2020002036A
Authority
MX
Mexico
Prior art keywords
tumor
associated antigen
proteins binding
binding nkg2d
nkg2d
Prior art date
Application number
MX2020002036A
Other languages
English (en)
Inventor
Prinz Bianka
P Chang Gregory
F Cheung Ann
Haney William
M Lunde Bradley
Du Jinyan
Wagtmann Nicolai
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MX2020002036A publication Critical patent/MX2020002036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen proteínas de unión multiespecíficas que se unen al receptor NKG2D, CD16 y un antígeno asociado a tumores, así como composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento del cáncer.
MX2020002036A 2017-08-23 2018-08-23 Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. MX2020002036A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762549201P 2017-08-23 2017-08-23
US201762558510P 2017-09-14 2017-09-14
US201762558514P 2017-09-14 2017-09-14
US201762558511P 2017-09-14 2017-09-14
US201762558509P 2017-09-14 2017-09-14
US201762566828P 2017-10-02 2017-10-02
US201762581357P 2017-11-03 2017-11-03
US201762608384P 2017-12-20 2017-12-20
PCT/US2018/047714 WO2019040727A1 (en) 2017-08-23 2018-08-23 BINDING PROTEINS FOR NKG2D, CD16 AND ANTIGEN ASSOCIATED WITH A TUMOR

Publications (1)

Publication Number Publication Date
MX2020002036A true MX2020002036A (es) 2020-03-24

Family

ID=65439284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002036A MX2020002036A (es) 2017-08-23 2018-08-23 Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.

Country Status (13)

Country Link
US (1) US20200231679A1 (es)
EP (1) EP3672993A4 (es)
JP (2) JP2020531525A (es)
KR (1) KR20200038530A (es)
CN (1) CN111315778A (es)
AU (1) AU2018322178A1 (es)
BR (1) BR112020003654A2 (es)
CA (1) CA3072919A1 (es)
IL (1) IL272706A (es)
MX (1) MX2020002036A (es)
RU (1) RU2020111554A (es)
SG (1) SG11201913968VA (es)
WO (1) WO2019040727A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
WO2021150598A1 (en) * 2020-01-20 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Affinity peptide conjugated with antioxidant for protection of proteins from oxidation
CN114437214B (zh) * 2020-11-03 2023-06-02 南京北恒生物科技有限公司 靶向lir1的抗体及其用途
WO2022143912A1 (zh) * 2020-12-31 2022-07-07 信达生物制药(苏州)有限公司 含异二聚体抗体Fc的蛋白以及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266014A2 (en) * 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
JP2009500346A (ja) * 2005-06-29 2009-01-08 ユニバーシティー・オブ・マイアミ 癌処置用の抗体−免疫細胞リガンド融合タンパク質
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
MX2008015524A (es) * 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
DK2222706T4 (en) * 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
DE102013019352A1 (de) * 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
SG10201906460PA (en) * 2014-03-05 2019-09-27 Ucl Business Plc Chimeric Antigen Receptor (Car) With Antigen Binding Domains to the T Cell Receptor Beta Constant Region
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
AU2016219785B2 (en) * 2015-02-20 2021-10-28 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
CA2990511A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
MA43874A (fr) * 2016-01-13 2018-11-21 Compass Therapeutics Llc Constructions de liaison à l'antigène immunomodulateur multispécifique
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
BR112019016424A2 (pt) * 2017-02-10 2020-04-07 Dragonfly Therapeutics Inc proteínas de ligação a bcma, nkg2d e cd16

Also Published As

Publication number Publication date
CA3072919A1 (en) 2019-02-28
AU2018322178A1 (en) 2020-02-20
RU2020111554A3 (es) 2022-01-19
JP2020531525A (ja) 2020-11-05
KR20200038530A (ko) 2020-04-13
CN111315778A (zh) 2020-06-19
RU2020111554A (ru) 2021-09-23
JP2023062184A (ja) 2023-05-02
IL272706A (en) 2020-04-30
BR112020003654A2 (pt) 2020-11-17
EP3672993A4 (en) 2021-10-27
SG11201913968VA (en) 2020-01-30
WO2019040727A1 (en) 2019-02-28
EP3672993A1 (en) 2020-07-01
US20200231679A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
AU2020267226B2 (en) Multispecific binding proteins targeting nkg2d, cd16. and trop2
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
MX2019013998A (es) Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
MX2021001510A (es) Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2020001257A (es) Proteinas que se unen a nkg2d, cd16 y flt3.
NZ738008A (en) Tigit-binding agents and uses thereof
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
MX2019013995A (es) Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor.
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2016017311A (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas.
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
AU2018271930A1 (en) A protein binding NKG2D, CD16 and a tumor-associated antigen
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
MX2022004430A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
MX2022013944A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
MX2020012273A (es) Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.